858-449-1310 contact@somatek.com


Progress Towards Universal Influenza Vaccine

Influenza vaccines typically coax the immune system to generate antibodies that recognize the head of hemagglutinin (HA), a protein that extends outward from the surface of the flu virus. The head is the most accessible regions of HA, making it a good target for the...

read more

The Interesting World of mRNA Vaccines

The Scientist published under the title "Moderna vs. Pfizer: Is There a “Best” mRNA Vaccine?" an interesting summary of the current data on effectiveness of the Pfizer and Moderna mRNA COVID-19 vaccines. As a somewhat accidental member of #team Moderna this helps to...

read more

A New Type of Antibody –

For a long time 5 antibody types have been known in mammals, IgG, IgM, IgA, IgE, and IgD, with IgG being the work horse in biotechnology. So it drew our attention that a group at Duke University has described a new type of anti-glycan antibody that binds to a patch of...

read more

Monoclonal for Alzheimer’s

On Monday FDA approved Biogen’s aducanumab, brand name Aduhelm, through a program called accelerated approval. Aduhelm is the first new medication for Alzheimer’s disease in nearly two decades. FDA’s decision was welcomed by patients and their families as a...

read more

RNA therapeutics

To those developing treatments for oncology, in the gene therapy space and many other fields it seemed for a long time that RNA-based therapies have many attractive properties but somehow just too many obstacles to overcome. Enter recent break-throughs in vaccine...

read more

Somatek looks back at 2020

It goes without saying, 2020 was a year with major challenges and disruptions. However, it was also a year of growth and new opportunities for the biotechnology industry and for Somatek. In the summer of 2020, Somatek moved into newly renovated laboratory facilities...

read more